Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Two different responses to the therapy were observed in a group of patients receiving the protease inhibitor indinavir. In one, suppression of virus replication occurred and has persisted for 90 weeks (bDNA, < 500 human immunodeficiency virus type 1 [HIV-1] RNA copies/ml). In the second group, a reb...
Guardat en:
| Publicat a: | J Virol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1997
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC191944/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9261388/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.71.9.6662-6670.1997 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
